Policy Research Institute News

This is a bulletin summarizing the activities and topics of the institute at the time.
Please note that some links to past materials may be broken.
Please refrain from reproducing or copying any text, images, etc. in Policy Studies Institute News without permission.

Summary	OPIR Views and Actions No.76 Summary (Japanese and English)]
The Pharmaceutical Industry at a Glance	Comparison of New Drug Approval Status in Japan, the U.S., and Europe (2024) The Number of New Drugs in the Development Pipeline in the U.S. Current Position of Drug Discovery Research in Japan A Survey of Preclinical Stage Alliances and Acquisitions: A Comparison of Japan and Other Countries Survey on Domestic Emerging Pharmaceutical Companies with Developed Products (EBPs) CDMO Utilization Environment in Japan
Points of View	Benefits and Challenges of Patient-Reported Outcome Measure (PROM) Interventions from a Systematic Review Trends in the Calculation of New Drugs, Focusing on the Supplemental Allowance: Trends Before and After the FY2024 NHI Reform (Survey through August 2025)

Summary	OPIR Views and Actions No.75 Summary (Japanese and English)]
The Pharmaceutical Industry at a Glance	Recent Trends in the Approval and Listing of Pediatric Drugs in Japan
Points of View	Recent Trends in Post-Marketing Surveillance and the Economic Evaluation of Post-Marketing Database Surveillance Economic Evaluation of Post-Marketing Database Surveillance Pharmaceutical Company Survey Report on Utilization of Public Databases (1) -Possibilities and Challenges of Utilization of Public Databases Pharmaceutical Company Survey Report on Utilization of Public Databases, etc. (2) -Organizing Stored Information and Use Cases Patient-Reported Outcome (Patient-Reported Outcome) from the Viewpoint of FDA Published Data Usage of Patient-Reported Outcome (PRO) Latest Trends in Patient-Reported Outcome (PRO) -Survey and Analysis Using Clinical Trial Registry Database

Summary	Policy Research Institute News No.74
The Pharmaceutical Industry at a Glance	Nationality of the Top Global Pharmaceutical Creators by Sales -Trends for 2023- (in Japanese) Trends in Diabetes-Related Specified Health Examination Data and Prescription Drugs in NDB Open Data
Points of View	Characteristics of New Drugs Approved in Japan - Survey and Analysis from the Viewpoint of NHI Calculation Status, etc.

Summary	Policy Research Institute News No.73
The Pharmaceutical Industry at a Glance	Comparison of New Drug Approval Status in Japan, U.S. and Europe (2023) Survey on Recent Trends in International Clinical Trials -Trends through 2023 and the Asian Region- (in Japanese) Trends in Cancer Medical Technology from NDB Open Data
Points of View	Trends in the Calculation Status of New Drugs with a Focus on Supplementary Drugs -Survey including the three times the drug was listed after the 2024 NHI drug price reform Results of the evaluation of HST at NICE in the U.K. and factors considered in decision-making in addition to ICER Ripple Effects of the Utilization of Medical Information Recent Trends in the Utilization of Medical Information as Seen in Pharmaceutical Company News Releases

Summary	Policy Research Institute News No.72
The Pharmaceutical Industry at a Glance	Recent Trends of Unapproved Drugs in Japan -In light of New Drug Approval Status in Japan and the U.S. by 2023
Points of View	How to Obtain Samples and Information for Research in the Field of Oncology Factors required by pharmaceutical companies when utilizing medical information

Summary	Policy Research Institute News No.71
Topics	Contribution of Science to Drug Discovery in Japan, the U.S. and Europe: Implications from Matched Data on Patents and Publications
Points of View	The Current State of Japanese Academia from the Perspective of Research Power Current Status of Secondary Use of Medical Information in the Pharmaceutical Industry Implications from Japanese papers on cost-effectiveness analysis: A case study of care cost calculation from a social standpoint
The Pharmaceutical Industry at a Glance	Drug Lag: Analysis of Factors Contributing to the Long-term Lag of Japanese Approved Products Nationality of Companies Generating Top Global Sales of Pharmaceuticals -Trends in 2022 Changes in Outpatient Care and Outpatient Prescription Drugs Influenced by the COVID-19 Pandemic as Seen in NDB Open Data

Topics	Forum on "The Value of Drugs and DTx for the Public" organized by the Policy Research Institute
Opinion	Next Generation Medical Infrastructure Act to be a better system
The Pharmaceutical Industry at a Glance	Nationality of Patent Generating Organizations for NME-Approved Products in Japan, the U.S. and Europe -Comparison of Approved Products Containing New Active Pharmaceutical Ingredients in Japan, the U.S. and Europe Development Status of Pharmaceuticals for Unmet Medical Needs Drug Lag: Analysis of the Lag Status of NMEs Approved in Japan Comparison of New Drug Approval Status and Examination Periods in Japan, the U.S. and Europe
Points of View	Cancer Prevention Efforts to Ensure Data Quality in Europe - Fit for purpose data to promote secondary use Current status of health literacy in Japan, policies and efforts to improve it Survey on Countries Conducting Clinical Trials - Comparison among Drug Discovery Modalities Status of inclusion of EQ-5D in clinical trial applications in each country Interpretation of academic research results for cost-effectiveness evaluation

Topics	Drug Lag: Characteristics of Japanese Unapproved Drugs with Pediatric Indications Part 1 - Rare Diseases Drug Lag: Characteristics of Unapproved Drugs with Pediatric Indications in Japan Part 2 -Anticancer Drugs
Opinion	The Value of Digital Therapeutics (DTx)
Points of View	Trends in Outcome Measurement Tools for Digital Therapeutics (DTx) -Survey Using Clinical Trial Databases Information flow in research use of genomic information Topics related to care from a pharmaceutical industry perspective Pipeline analysis of major Japanese pharmaceutical companies - Comparison of in-house origin and external in-licensing Public Attitudes and Actions on Saving Healthcare Costs -Report on the Results of a Survey on Attitudes toward Prices, Systems and Value of Drugs, Part 4-. Evaluation of the price adjustment portion of cost-effectiveness assessment
The Pharmaceutical Industry at a Glance	Approval Status of Drugs for Unmet Medical Needs Business revenue structure of the pharmaceutical industry in terms of tax burden

Topics	Economic Contribution of the Pharmaceutical Industry: A Consideration from Nominal and Real Gross Value Added
Points of View	Innovativeness of New Drugs and Price Premiums: A Pilot Study of New Drugs with No Similar Drugs The Value of Pharmaceuticals as Valued by the Public: A Report on the Results of a Survey of Public Attitudes toward the Price, System, and Value of Pharmaceuticals, Part 2 Public Expectations, Desired Means, Opportunities and Timing of Knowing about Prices, Systems and Values of Drugs - Report on the Results of a Survey on Public Attitudes toward Prices, Systems and Values of Drugs Part 3 The past and future of the cost-effectiveness evaluation system in Japan - Implications from a comparison between Japan and the UK Current Status of Biobank (UK Biobank) Utilization Characteristics of the Global EHR/PHR Environment -Toward the Promotion of Utilization of Health and Medical Data in Japan Co-Creation in R&D of Japanese Pharmaceutical Companies -Implications from the Trends of External Alliances between Japanese Major Pharmaceutical Companies and Drug Discovery Ventures Diabetes Mellitus Investigation of Drug Development Time -Do Differences in Modality and Disease Matter? Global Trends and Development Lag Analysis of Products in Phase 3 Development
The Pharmaceutical Industry at a Glance	Comparison of the launch status of the top 300 pharmaceutical products in the world in terms of sales in Japan, the U.S. and Europe New Drugs Approved in Japan and Their Review Periods - Survey of Approval Results in 2022 and Trends Over Time

Topics	Drug Lag: Impact on Business Investment Priorities - Results of a Survey of Pharmaceutical Companies on Business Investment Priorities in Japan Drug Lag: Comparison of Unapproved Drugs in Japan and Europe - Based on U.S. drug approvals from 2010 to 2021 Econometric Analysis of the International Diffusion of New Drugs: Focusing on Japanese and European Approval of New Drugs Approved in the United States
Points of View	Cardiovascular Disease Life Science Communication Public Awareness and Interest in Pharmaceutical Prices and Systems -Report on the Results of a Survey on Public Awareness of Pharmaceutical Prices, Systems and Values, Part 1-. Valuation of Pharmaceuticals from the perspective of HST at NICE in the U.K. Trends in medical record integration as seen in the case of COVID-19 Characteristics of Intellectual Property Surrounding Digital Health -Based on Global Trends and Analysis of DTx Companies in Japan and the U.S. Survey on Development Trends of New Modalities - mRNA and Microbiome
The Pharmaceutical Industry at a Glance	Nationality of the top drug generators in terms of global sales -Trends in 2021 Comparison of New Drug Approval Status and Review Periods in Japan, the U.S., and Europe -Based on the Approval Status of Biopharmaceuticals

On the Occasion of the 20th Anniversary	Director, Pharmaceutical and Industrial Policy Research Institute Sadao Nagaoka Chairman, Japan Pharmaceutical Manufacturers Association Joji Nakayama Chairman, Japan Pharmaceutical Manufacturers Association Tadaharu Goto Chairman, Chugai Pharmaceutical Co. Osamu Nagayama Second Director, Pharmaceuticals and Industrial Policy Research Institute Yoshihito Takahashi Third Director, Pharmaceuticals and Industrial Policy Research Institute Hitoshi Okuda
Topics	Evaluation of Innovativeness by Comparison of Similar Drugs: Analysis Using Matched Data with Comparison Drugs Data Integration and Distribution Platform Based on Individuals (2) - Distributed Data Distribution by PLR (Personal Life Repository)
Points of View	Level and Direction of Drug Discovery Innovation: Importance of Demand and Incentives Toward Early Development of AI Human Resources in the Pharmaceutical Industry Exploring the trend of practical application of CAR-T cell therapy based on related literature and citation count information New Payment Methods for High Cost Drugs -Trends in Western Countries Usage of Anti-Tumor Drugs under the DPC System (DPC/PDPS)
Opinion	Proposal of a Consortium Concept for the Dissemination of Solutions Leading to Early Diagnosis and Continuation of Treatment A Study on the Regulation of Pharmaceutical Advertisements (Part 2) - Toward the Realization of Patient Centricity
The Pharmaceutical Industry at a Glance	Current Status of Digitalization Promotion in Pharmaceutical Companies -CDO/CIO and Establishment of Digitalization Promotion Department New drugs approved in Japan in 2018 and their review periods Comparison of Patent Term and Reexamination Term for Drugs Containing New Active Ingredients-2 Status of Licensing-in in the Pharmaceutical Industry - Comparison of Japanese and Global Companies

Points of View	Trend Analysis of Target Molecules of Small Molecular Drugs - Survey of Products Launched in the Past 47 Years Examination of formulation and dosage form of biopharmaceuticals (antibody drugs) -Improvement of convenience and future development Approval status and review period of new drugs in recent years - based on the approved products in 2016 Nationalities of the top-selling global drug generators and key distributors -Trends in 2015
Topics	Impact of the New U.S. Administration on the Japanese Pharmaceutical Industry - Obamacare and the NHI Price Review Utilization of Personal Health Record "Utilization of Big Data in Medical and Health Fields" Report IoT-based Medication Management - Toward Improving Medication Adherence Rates Marketed drugs used in clinical trials for designated intractable diseases
The Pharmaceutical Industry at a Glance	Success rate of clinical development

Opinion	Exporting Pharmaceuticals to the World
Points of View	Patient-Focused Drug Development - Utilizing Patients' Voices in New Drug Development Training for Physicians on Clinical Trials and Clinical Research Preventive Medicine by Comprehensive Genome Analysis Efforts in Packaging and Formulation to Prevent Mishandling and Improve Adherence
Topics	Is ¥2.4 trillion in funds being diverted overseas due to over-importation of pharmaceuticals?
The Pharmaceutical Industry at a Glance	Efforts in drug development - with a focus on new drug approvals in the last 5 years Is ¥2.4 trillion in funds being diverted overseas due to over-importation of pharmaceuticals?

Topics	New Drugs and the Probability of Care: Prevention of Disease Severity and Prolonged Disease Drug Lag: Can Unapproved Drugs Meet Japan's Unmet Medical Needs? Drug lag: Why are unapproved drugs increasing?
The Pharmaceutical Industry at a Glance	Changes in FDA Approval Trends for Antineoplastic and Neurological Drugs - Background to the Increase in Unapproved Drugs in Japan Survey of International Clinical Trials in Recent Years Development and Approval Status of Drugs for Unmet Medical Needs -Trends in 2022
Points of View	Probability of Success Analysis of Drug Discovery -Focusing on Clinical Trials Acceleration of Digital Medicine Development in Japan -Personnel and Places to Embody Clinical Needs The Latest Trends in Flail In response to the changes seen in R&D trends in vaccines for the prevention of infectious diseases Why new drugs reach patients 60 days after approval -The birth of the 60-day rule, its current status, and its future

Opinion	Status and Issues of Antimicrobial Drug Development in Japan, Europe and the United States The Latest Trends in Patient and Public Involvement (PPI) - A Growth Phase of Patient and Public Involvement
Points of View	Creation of Vaccines for Prevention of Infectious Diseases Consideration of Outcome Indicators for DTx Reimbursement - Toward Diverse Value Assessment Based on the Latest Trends in the U.S. and Europe Current Status and Future Prospects of Gene Therapy in Practical Use Health Status of the Elderly from the Perspective of Nursing Care System Data -Analysis Using Complementary Indicators of Healthy Life Expectancy The Latest Trends in Patient Reported Outcome (PRO) - Survey and Analysis Using Clinical Trial Registration Database
The Pharmaceutical Industry at a Glance	Trends in the Market Capitalization of the Pharmaceutical Industry New Drugs Approved in Japan and Their Review Periods - Approval Results for 2021 and the Current Status of Globalization of the Japanese Market Nationality of companies generating top pharmaceutical sales in the Japanese market
Topics	Workshop on the Value of Drugs: Considering the Value of Drugs and Their Evaluation from the Perspective of the Public and Patients," organized by the National Institute for Policy Studies

Opinion	Intangible fixed asset investment for future growth - Business characteristics of pharmaceutical companies Profit sharing of R&D-based pharmaceutical companies: Dividends
Topics	Congressional Budget Office Report "Research and Development in the Pharmaceutical Industry Continued : The Value of Drugs and Medical Consultations, etc. as Considered by the General Public -Comparison by Presence or Absence and Other Attributes
Points of View	The use of wearable devices in drug development Symbiosis with Disease in Dementia Suggestions for future "co-creation drug discovery" -Learning from the research and development of COVID-19 therapeutics and vaccines
The Pharmaceutical Industry at a Glance	Drug Lag: Status and Characteristics of Unapproved Drugs in Japan Drug Lag: Launch Status of NMEs in Japan -Comparison of launch timing with the U.S. and Europe

Topics	Price premiums of new drugs relative to comparator drugs: Analysis using matched samples from Japan, the U.S., and Europe Issues on the nature of public medical insurance benefits The Value of Medicines and Medical Consultations, etc. as Considered by the General Public -A Web-based Survey Based on the Corona Disaster
Points of View	Analysis of decision-making factors in HTA institutions Survey on modalities and indications in the drug development pipeline Living with Disease in Cancer Survivors Utilization of Data Obtained in Daily Life -Approach in Smart Cities
The Pharmaceutical Industry at a Glance	Nationality of companies creating NME-approved products in Japan, the U.S., and Europe - Focus on approved products from 2010 to 2019 New Drugs Approved in Japan and Their Review Periods -A Survey of Approval Results in 2020 and Trends in the Past 10 Years-. Characteristics of the top products in terms of overseas sales of major Japanese pharmaceutical companies

Opinion	Response to the COVID-19 pandemic in the pharmaceutical industry and its future
Topics	Trends in Privacy Protection Technology and Implications for the Utilization of Medical Healthcare Data Trends in the Establishment of a New Regulatory Framework for Software as a Medical Device in Japan and the U.S. Current status of next-generation healthcare in Japan -- with a focus on pharmaceutical companies, government and ministry trends from 2010 to 2020
Points of View	Utilization of Data Obtained in Everyday Life - - Living Lab Initiatives Current status of evaluation and utilization of labor productivity outcomes in pharmaceuticals
The Pharmaceutical Industry at a Glance	Survey on New Drug Discovery Companies (Originators) from the Perspective of Drug Development Pipeline by Drug Discovery Modality Nationality of the Top Pharmaceutical Discovery Companies by Global Sales --2019 Trends---. Development Status of Drugs for Unmet Medical Needs --Trends for 2020 Comparison of New Drug Approval Status and Review Periods in Japan, the U.S., and Europe --Focusing on 2019 Approval Results

Topics	Global R&D Trends of Drugs for Prevention and Treatment of Novel Coronavirus Infections (COVID-19) Data Utilization in a Novel Coronavirus Infection Epidemic --Focusing on the Case of Contact Confirmation Apps
The Pharmaceutical Industry at a Glance	A Study on Drug Lag of Biopharmaceuticals Trends in Clinical Development of New Drugs by Chinese Pharmaceutical Companies
Points of View	Spillover Value of Pharmaceuticals to Caregivers' Quality of Life and Burden of Care - From the Viewpoint of Outcome Evaluation

Opinion	A New Look at "Right" for "Active Medicines" - Aiming to Realize and Maximize the Value of Pharmaceuticals Toward the realization of "Pharma as a Service" -What is required of the pharmaceutical industry in data-driven healthcare
The Pharmaceutical Industry at a Glance	New drugs approved in Japan in 2019 and their review period Orphan drug development trends -Analysis of FDA-approved orphan drugs in Japan Development and approval status of drugs for unmet medical needs -Trends in 2019 Comparison of pediatric indications of new drugs between Japan and the U.S.
Points of View	Life Science Clusters that Create and Nurture New Drugs -Implications from Boston's Innovation Ecosystem Toward Further Utilization of Medical Information -From the Perspective of Personal Information Protection Multifaceted Value of Medicines from the Perspective of NICE Evaluation in the U.K. -Analysis of Medicines for Rare and Intractable Diseases
Topics	Considering the Ecosystem in the Healthcare Sector -Discussion Points of the Data Ecosystem New Trends in Domestic Private Health Insurance on Access to Health Care Services

Opinion	Patient and Public Involvement in the Healthcare Sector The Future of the Pharmaceutical Industry from the Perspective of Digital Health - As a Member of "Data-Driven Healthcare Overview of the current system in Japan regarding Beyond-The-Pill
Topics	Value-Added Creation and Contribution of R&D-Oriented Manufacturing Industry --From a Tax-Bearing Perspective Overview of "Security and Privacy" Regulations for Health Data Platforms in the U.S. and Europe Toward Standardization of PHRs -- Perspective of Quality Data Collection
The Pharmaceutical Industry at a Glance	Japan's Presence in the Pharmaceutical Market -Analysis of Overseas Sales Share of Japanese Companies Nationalities of companies generating top global sales of pharmaceuticals -Trends in 2018 Analysis of Countries Participating in International Clinical Trials in Recent Years --Based on ClinicalTrials.gov, a Clinical Trial Registration System--. Comparison of New Drug Approval Status and Review Periods in Japan, the U.S. and Europe - Focusing on 2018 Approval Results Survey on Development Trends of Drug Discovery Modalities - Perspectives on Discovery, Acquisition and In-licensing by Company Type
Points of View	How to utilize medical technology evaluation in the field of medical health - in view of institutionalization of cost-effectiveness evaluation Utilization of Clinical Trial Control Groups in Clinical Development

Opinion	Preparation of the Pharmaceutical Industry for Future Healthcare - Based on the Interim Report of the Future Innovation WG
The Pharmaceutical Industry at a Glance	Comparison of Financial Indicators among R&D-Oriented Manufacturing Industries - Based on the Business Characteristics of the Pharmaceutical Industry R&D Status of New Modalities in Japan - Based on a Questionnaire Survey by the Pharmaceutical Manufacturers Association of Japan A Comparison of the Launch Status of the World's Top 300 Products in terms of Sales in Japan, the U.S. and Europe: Is the Drug Lag Being Resolved? Countries where drugs approved under special regulatory measures in Japan, the U.S., and Europe are created Status of spin-out companies from major global pharmaceutical companies
Topics	Trends in Clinical Trials for Designated Intractable Diseases - Focusing on Drug Combination Therapy Differences in Priority of Needs for Therapeutic Drugs between the General Public and Physicians (Preliminary Survey)
Points of View	Health in your pocket - Status of Digital Therapeutics clinical trials using video games and mobile apps Considering the "Quality" of Lifecourse Health Data - Perspectives on the realization of data-driven healthcare Recent Trends in Patient Reported Outcome (PRO) - Survey and Analysis Using Clinical Trial Registry Databases Regulatory Reform in the Health Care Sector - A Turning Point in One Street

Topics	The Value of Drugs: A Study by the "Study Group on the Value of Drugs" of the Policy Research Institute (PRIRI) Data Integration and Distribution Platform Based on Individuals - Toward the Era of Individuals Managing Data
Points of View	Establishment of Reference Values for Cost-Effectiveness Evaluation - Verification of the Variability of the Amount of Willingness to Pay under Different Conditions Economic value of the curative effect of innovative drugs - Contribution of drugs and surgery to inpatient outcomes Toward the Widespread Use of "Virtual" Clinical Trials -Web-based and Site-less Clinical Trials Access to the Next Generation of Preventive Medicine
The Pharmaceutical Industry at a Glance	Comparison of New Drug Review Periods in Japan, the U.S., and Europe - Focusing on 2017 Approval Results Trends of Research Alliances in Pharmaceutical Companies -From Press Releases of Each Company Survey of Development Trends of New Modalities - Focusing on Nucleic Acid Drugs, Gene Therapy and Cell Therapy Trends of AI startups in pharmaceutical R&D Patent Productivity in the Pharmaceutical Manufacturing Industry Nationality of the Top Global Sales Drug Creators - 2017 Trends Survey on the Leaders in the Creation of Innovative Medicines -From the Origin Analysis of the Top Global Sales of Medicines

Policy Research Institute News

Latest Issue No.76 November 2025

No.75 July 2025

No.74 March 2025

No.73 November 2024

No.72 Issued Jul. 2024

No.71 Issued Mar. 2024

No.70 Issued in Nov. 2023

No.69 Published in Jul. 2023

No.68 Published in Mar. 2023

No.67 Published in November 2022

No.66 Published in Jul. 2022

No.65 Issued Mar. 2022

No.64 Published in Nov. 2021

No.63 Jul. 2021

No.62 Issued Mar. 2021

No.61 Issued in Nov. 2020

No.60 Issued Jul. 2020

No.59 Issued Mar. 2020

No.58 November 2019 Issue

No.57 Issued Jul. 2019

No.56 March 2019 Issue 20th anniversary issue

No.55 Issued Nov. 2018

No.54 July 2018 Issue

No.53 March 2018 Issue

No.52 November 2017 Issue

No.51 July 2017 Issue

No.50 March 2017 Issue

No.49 November 2016 Issue

No.48 Published Jul. 2016

No.47 March 2016 Issue

No.46 Published in Nov. 2015

No.45 Published Jul. 2015

No.44 March 2015

No.43 Published in November 2014

No.42 Published Jul. 2014

No.41 March 2014

No.40 November 2013

No.39 July 2013

No.38 March 2013

No.37 November 2012

No.36 Jul. 2012

No.35 March 2012

No.34 November 2011

No.33 July 2011

No.32 February 2011

No.31 October 2010

No.30 April 2010

No.29 January 2010

No.28 August 2009

No.27 March 2009

No.26 December 2008

No.25 July 2008

No.24 February 2008

No.23 August 2007

No.22 March 2007

No.21 October 2006

No.20 June 2006

No.19 February 2006

No.18 October 2005

No.17 June 2005

No.16 February 2005

No.15 October 2004

No.14 July 2004

No.13 March 2004

No.12 November 2003

No.11 Jul. 2003

No.10 March 2003

No.9 December 2002

No.8 October 2002

No.7 July 2002

No.6 May 2002

No.5 March 2002

No.4 Jan. 2002

No.3 November 2001

No.2 September 2001

No.1 July 2001

Site Search

Points of View	Trends in Payment Systems for Outcome-Based Drugs -Shift from "Quantity" to "Quality" in Healthcare Trends in AI utilization mainly by member companies of the Pharmaceutical Manufacturers Association of Japan -From a survey of media information Stage of consideration of social security system reform -Central conference body for revision of medical fees A Study on the Regulation of Pharmaceutical Advertisements - From the Perspective of Risk Communication between Patients and Pharmaceutical Companies
The Pharmaceutical Industry at a Glance	A Glimpse into the Self-Medication Situation in Japan from the Data - Perspectives on the Trend of Switch OTC Drugs Transition of the world's top pharmaceutical companies in terms of sales and their dependence on top-selling products - Positioning of Japanese companies in the world Countries Generating Orphan Drugs Approved in Japan -Fiscal Years 2008 to 2017 Women in the Pharmaceutical Industry and Corporate Performance - Based on the Database of Companies Promoting Women's Activities, Ministry of Health, Labour and Welfare, etc.
Topics	Construction of a Medical Health Big Data Platform through PPPs (Public Private Partnerships) - Significance of Industry-Academia-Government Collaboration for the Development of Disease Cures Introduction of "DDrare," a database of designated intractable diseases

Opinion	Expectations for the "Guidelines for the Promotion of Optimal Use
Points of View	Business Models of R&D-Oriented Domestic Pharmaceutical Companies - Sustained Fulfillment of Social Mission
Topics	Pharmaceutical Industry Vision in the Public and Private Sectors -Warming up and Renewal How to Handle Productivity Losses in Health Economic Evaluation Comparison of New Drug Review Periods in Japan, the U.S., and Europe -Analysis Based on 2016 Approval Results Utilization of Real World Data with a Focus on Patient Registries - From Clinical Trial Streamlining to Beyond Modality Analysis of Drugs Used in Clinical Trials for Designated Intractable Diseases Addressing Unmet Medical Needs with Biopharmaceuticals
The Pharmaceutical Industry at a Glance	Nationality of the Top Global Sales Generators of Pharmaceuticals - 2016 Trends Development and approval status of drugs for unmet medical needs -Trends in 2017 Trends in the number of new drug target molecules

Points of View	Target molecules and molecular weights of small molecule drugs -Survey from products launched in the past 47 years Production Trends of Biopharmaceuticals (Antibody Drugs) -Analysis from Sales Weight Comparison of Patent Term and Reexamination Term for Drugs Containing New Active Ingredients
Topics	Clinical Research Utilizing IoT - Benefits and Future Challenges - Report of "Big Data Utilization and Study Group on Medical and Health Fields Efforts to Improve Treatment Continuation Rates Using ICT
The Pharmaceutical Industry at a Glance	Success or Failure of Clinical Development from the Perspective of Company and Product Characteristics

Points of View	Number of countries in which patents have been filed for the world's top-selling drugs Survey of R&D Trends in Biopharmaceuticals (Antibody Drugs) - Molecular Structural Changes toward Next-generation Antibodies Trends in the Number of Published Patents for Small Molecular Compounds by Japanese Pharmaceutical Companies
Topics	Movement toward AI (Artificial Intelligence) Drug Discovery - What is Deep Learning? ～ Report on "Big Data Utilization and Study Group on Health and Medical Fields Big Data for Better Outcomes in Europe Trends in the Government's Promotion of R&D in the Medical Field - with Reference to the Budget and Progress of the Cooperative Projects of Each Ministry Vaccines for Prevention of Infectious Diseases in Japan
The Pharmaceutical Industry at a Glance	Nationalities of the top-selling pharmaceutical generators and key distributors in the world - trends in 2014 Current Status of Orphan Drugs in Japan, the U.S. and Europe -2010-2015

Points of View	Changes in the Business Environment Surrounding Pharmaceutical Companies and Mid-term Business Plan Survey on R&D Trends of Biopharmaceuticals (Antibody Drugs) -Expansion of Indications and Target Molecules-. Research Activities of Drug Discovery Chemists in Companies
Topics	Learning Healthcare System -Verification and Improvement of Medical Care with Real Clinical Data- Report of "Big Data Utilization and Study Group in the Health and Medical Field Medical Information Databases in the U.S. Accelerating Medicines Partnership in the U.S. Cooperation with External Organizations of Domestic Pharmaceutical Companies -A Study Focusing on Annual Securities Reports- (Japanese only) Priority Review and Characteristics of New Drugs in the Approval Process
The Pharmaceutical Industry at a Glance	Sales Share of Domestic Pharmaceutical Companies in the Global Market First-in-Class in the U.S. Research Trends in the Developmental Origins of Health and Disease (DOHaD) Hypothesis

Opinion	Light and Shadow of Open Innovation
Points of View	Infrastructure Development Desired for Big Data Utilization -Current Status and Challenges in the Medical Field Creation of Pharmaceuticals from Academia - Based on the case study of obtaining regulatory approval through the use of investigator-initiated clinical trials Analysis of Requests for Improvement in the Approval Review Process - Based on the Survey on Clinical Development and Review Periods of New Drugs (2013 Results)
Topics	Status of Research and Development of Small Molecular Drugs and Biopharmaceuticals Development Trends of Drugs for Intractable Neurological Diseases with High Unmet Medical Needs
The Pharmaceutical Industry at a Glance	Status of removal of conditions for investigation of all cases during the reexamination period for new drugs International comparison of the number of major basic and clinical medical papers published Status of Utilization of Female Researchers in the Pharmaceutical Industry -Activities of Female Doctoral Talent

Opinion	Expectations for the Japan Agency for Medical Research and Development (AMED)
Points of View	Registration Status of Japanese, Korean, and Chinese Versions of the PRO Evaluation Tool -Examination by the Global Database PROQOLID Survey of Business Models of Japanese Pharmaceutical Companies as Seen in Press Releases
Topics	Voluntary Application of IFRS (International Financial Reporting Standards) by Pharmaceutical Companies
The Pharmaceutical Industry at a Glance	First-in-Human Trial Countries in Clinical Trial Registries Research Status of Domestic Pharmaceutical Companies from the Viewpoint of Patents Number of Health Economics Research Papers in Recent Years

Opinion	An Attractive Place for Drug Discovery Open to the World
Points of View	Clinical Development of New Drugs and Review Periods -2013 Results Special Regulatory Measures for New Drug Approval Keyword 〈explanation〉Special Measures on Pharmaceutical Affairs in the U.S., Europe and Japan
Topics	The European Medicines Agency's Initiatives for Early Patient Access to New Medicines -Adaptive Licensing" - a topic of ongoing debate
The Pharmaceutical Industry at a Glance	Drug Discovery and Rights Attribution from the Perspective of Nationality Origins of the Development Pipeline of Japanese Pharmaceutical Companies

Points of View	Use of Health-Related Quality of Life (QOL) Information in the Appendix - Status of Use in Japan, the U.S., and Europe, and Noteworthy Case Studies Status of International Clinical Trials -Analysis by Number of Trials Conducted
The Pharmaceutical Industry at a Glance	Development Status of Drugs for Unmet Medical Needs -Trends in 2013 Research Trends of Early Diagnostic Biomarkers

Points of View	Drug repositioning and rare disease innovation Neglected Tropical Diseases" and Pharmaceutical Industry Initiatives - Consideration of Drug Needs in Emerging Countries Trends and Challenges in the Use of Pharmacogenomics Impact of Biomarkers on Productivity of Drug Development Industry-academia-government consortium support and incentives for companies to invest in R&D Expansion of "pre-competitive collaboration Effects of Policies to Promote the Use of Generic Drugs
Topics	International comparison of the number of major basic and clinical medical papers published
The Pharmaceutical Industry at a Glance	Use of Foreign Clinical Trial Data for New Drugs Approved in Japan Launch period for the world's top 100 selling products